What distinguishes the human evidence for BPC-157 and LL-37?

BPC-157 has three full primary human reports and two controlled groups known only from meeting abstracts in the reviewed FDA inventory. Native topical LL-37 has three distinct published wound-trial populations. Those are different indications and cannot establish a winner.

Did LL-37 prove wound healing or infection treatment?

No. A small venous-ulcer pilot and a diabetic-foot-ulcer cream trial had selected wound signals; a 148-person venous-ulcer trial found no significant full-population healing benefit. The diabetic-foot-ulcer trial did not significantly reduce measured aerobic bacterial colonization.

Are either peptide or their combination established treatments?

Neither is an FDA-approved medicine in this review. No direct comparison or combination treatment study was identified in the selected sources; safety and benefit cannot be inferred from separate studies.

BPC-157 vs LL-37: Evidence and Limits (2026)

Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.

What is being compared?

BPC-157 is a synthetic 15-residue gastric-peptide fragment investigated for tissue injury and mucosal protection. LL-37 is a 37-residue peptide processed from human cathelicidin precursor hCAP18; endogenous wound expression and laboratory antimicrobial activity are not themselves treatment outcomes. FDA BPC-157 briefing · LL-37 identity, PMID 8681941

Evidence question	BPC-157	LL-37
Human intervention	Three small full reports plus two abstract-only controlled groups in FDA’s reviewed inventory	Three published native topical wound-trial populations; a separate four-person intratumoral registry cohort
Therapeutic-claim grade	Low: heterogeneous and incompletely reported human work	Low: condition-specific, mixed topical results
What remains unproved?	Tendon, muscle, general gut-healing efficacy and long-term safety	General wound, infection, systemic and cancer benefit

What the studies actually found

FDA’s 2026 BPC-157 review distinguishes an abstract-only phase 1 tolerability group and ulcerative-colitis controlled group from three full primary reports: a retrospective knee series, uncontrolled interstitial-cystitis pilot and two-person intravenous pilot. The controlled ulcerative-colitis abstract is too incomplete to establish efficacy or safety; none validates tendon or muscle repair in people. FDA briefing · knee report, PMID 34324435 · cystitis pilot, PMID 39325560 · IV pilot, PMID 40131143

A 34-person venous-ulcer pilot reported selected healing signals with native topical LL-37. A later 148-person trial found no significant full-population healing benefit, although a large-ulcer subgroup analysis was post hoc. A separate diabetic-foot-ulcer cream trial found improved granulation measures without a significant change in measured aerobic bacterial colonization. These outcomes do not establish broad antimicrobial treatment. LL-37 topical pilot, PMID 25041740 · larger phase IIb trial, PMID 34687253 · diabetic-foot-ulcer trial, PMID 37480520

The completed NCT02225366 melanoma record posts results for only four intratumoral LL-37 participants; it is not an additional wound population or proof of antitumor benefit. An oral COVID-19 trial tested engineered L. lactis expressing LL-37, not purified peptide; its overall viral-negative-time result was nonsignificant. PMID 37605995

Neither mechanism nor one peptide’s source count provides a head-to-head efficacy ranking. FDA reports insufficient safety information for compounded preparations of both peptides, with substance-specific concerns. FDA compounding safety review

This selected-source comparison is educational and does not provide treatment or combination guidance.

BPC-157 vs LL-37

BPC-157

LL-37

What is being compared?

What the studies actually found

View Full Dossiers

Stay Updated on Peptide Comparisons